Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002152
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of WF 10 IV Solution in Patients With Advanced HIV Disease
Sponsor:
Oxo Chemie GmbH
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Randomized Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of WF 10 IV Solution TCDO in the Management of Patients With Advanced HIV Disease
Status:
COMPLETED
Status Verified Date:
1996-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe and effective to give WF 10 TCDO to patients with advanced HIV disease who cannot or will not take zidovudine didanosine zalcitabine or stavudine This study also examines how TCDO affects the levels of HIV in the body TCDO is a solution delivered through a vein
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| WF10-94-US-002 | None | None | None |